Monalizumab

Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

Retrieved on: 
Wednesday, May 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, PTCL, Monalizumab, Abstract, CT, AACR, Antibody-drug conjugate, IO, Coeliac disease, American depositary receipt, Cancer, Acute lymphoblastic leukemia, American Association for Cancer Research, NK, Research, NSCLC, Lung cancer, AstraZeneca, Acute myeloid leukemia, ASCO, ATM, AML, American Society of Clinical Oncology, Patient, SS, CD123, Annual general meeting, Webcast, Sanofi, Nature Biotechnology, ADC, Poster, Mycosis fungoides, CRT, Society, IND, BCMA, Fine chemical, Pharmaceutical industry, Vaccine, Takeda, Innate Immunotherapeutics

Innate continues to see progress for lacutamab with final data from the TELLOMAK Phase 2 trial for both mycosis fungoides (MF) and Sézary syndrome (SS) expected in H2 2023.

Key Points: 
  • Innate continues to see progress for lacutamab with final data from the TELLOMAK Phase 2 trial for both mycosis fungoides (MF) and Sézary syndrome (SS) expected in H2 2023.
  • Cash, cash equivalents and financial assets of the Company amounted to €135.0 million as of March 31, 2023.
  • Cash, cash equivalents and financial assets as of March 31, 2023 do not include the $5.0 million payment to be received from Takeda.
  • Revenues for the first three months of 2023 amounted to €26.0 million (€2.6 million for the same period in 2022).

Innate Pharma Reports First Half 2022 Financial Results and Business Update

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cetuximab, Termination, Trial of the century, COVID-19, Sarbanes, Risk, Net, Research, Supervisory board, Sarbanes–Oxley Act, Company, Acquisition, Review, Investment, SAS, Depreciation, Intangibles, AstraZeneca, Nasdaq, IAS, Accounting, BNP Paribas, Risk factor, Insurance, Collection, Board of directors, AMF, Rale, Classification, Federal Executive Boards, Lawyer, Transition, Mission statement, Lithium, Pharmaceutical industry, Health insurance, Renewable energy, Cryptocurrency, Online gambling, Moxetumomab pasudotox, Monalizumab, Sanofi

The fall in other expenses of 0.8m mainly results from non recurring provisions for liabilities and charges booked in the 1st half of 2021 reversed in 1st half of 2022.

Key Points: 
  • The fall in other expenses of 0.8m mainly results from non recurring provisions for liabilities and charges booked in the 1st half of 2021 reversed in 1st half of 2022.
  • The Company has not made any investments in tangible, intangible or significant financial assets during the first half of 2022 and 2021.
  • Furthermore, the conflict triggered by Russia's invasion of Ukraine on February 24, 2022 had no significant direct or indirect consequences on the Company's interim consolidated financial statements for the first half of 2022.
  • An update of that risk is presented in note G) of the half-year management review as of June 30, 2022.

Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

Retrieved on: 
Monday, September 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, AstraZeneca, Neoplasm, Lung cancer, European Society for Medical Oncology, Technology, Cancer, NK, Tumor microenvironment, Publication, NCR1, Novo Nordisk, Therapy, IPHA, Circulating tumor DNA, PTCL, Poster, ESMO, Natural killer T cell, Lymphoma, DNA, Euronext Paris, CTCL, Chemoradiotherapy, IPH, Lymphatic system, Antibody, KIR, Sanofi, Family, Immune system, KIR3DL2, NSCLC, Tetra, Oncology, CD16, T-cell lymphoma, Mycosis fungoides, Peripheral T-cell lymphoma, Bristol Myers Squibb, Patient, Vaccine, Intrinsic and extrinsic properties, Monalizumab, MD, Nasdaq

Rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

Key Points: 
  • Rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.
  • It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL).
  • ANKET (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Retrieved on: 
Monday, August 1, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Antibody, Time, Bristol Myers Squibb, Euronext Paris, Natural killer T cell, Chemoradiotherapy, Novo Nordisk, Large-cell lung carcinoma, Trial of the century, Neoplasm, PFS, Immune system, Safety, Head, Lymphatic system, Tumor microenvironment, Cancer, Progression-free survival, OS, Quality of life, Cetuximab, PD-L1, Immunotherapy, NSCLC, Lung cancer, Patient, IPHA, NK, AstraZeneca, Neck, Sanofi, IPH, Pharmaceutical industry, Vaccine, Monalizumab, MD, Nasdaq, Monalizumab, Intrinsic and extrinsic properties

Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued.

Key Points: 
  • Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued.
  • The INTERLINK-1 Phase 3 study was intended to further evaluate a novel immunotherapy regimen following the promising signals observed in a non-randomized Phase 1b/2 study of head and neck cancer.
  • Including the $50 million payment triggered by dosing the first patient in the Phase 3 PACIFIC-9 clinical study, Innate Pharma has received $450 million to date.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Retrieved on: 
Friday, June 3, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Adenosine triphosphate, Sanofi, Large-cell lung carcinoma, Head, IPH, Euronext Paris, B cell, Cancer, Adenosine, CD73, Patient, Tumor microenvironment, AstraZeneca, Bristol Myers Squibb, ATP, Immune system, Antibody, Lung cancer, AMP, Polyphosphate, Systematics – study of multi-term systems, Neck, IPHA, Novo Nordisk, PD-L1, CD39, Adenosine monophosphate, Pharmaceutical industry, Vaccine, Fine chemical, Monalizumab, Nasdaq, EU, MD, Intrinsic and extrinsic properties

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), will advance into a Phase 2 clinical trial in lung cancer.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), will advance into a Phase 2 clinical trial in lung cancer.
  • We are very pleased that our collaboration with AstraZeneca continues to advance with this Phase 2 trial of our anti-CD39, IPH5201.
  • In addition to IPH5201, Innates anti-CD73 program, IPH5301 is in a Phase 1 study, said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.
  • About the Innate Pharma-AstraZeneca Multi-Term Agreement:
    In October 2018, Innate Pharma and AstraZeneca entered into a development collaboration that included an option agreement for IPH5201, an anti-CD39 blocking monoclonal antibody.

Innate Pharma Reports First Quarter 2022 Financial Results and Business Update

Retrieved on: 
Tuesday, May 10, 2022
Biotechnology, Pharmaceutical, Health, Oleclumab, GEMOX, Cetuximab, Trastuzumab, PFS, B-ALL, American Association for Cancer Research, PTCL, Safety, Myelodysplastic syndrome, Investor, Tetra, Antibody, MF, Immune system, Company, ESMO, Patient, American Journal of Clinical Oncology, American Association, IPH, Oncology, Congress, Sanofi, Research, ORR, ATM, KIR3DL2, American depositary receipt, Novo Nordisk, Telephone, European Society for Medical Oncology, Association, Acute myeloid leukemia, Euronext Paris, NSCLC, AACR, Acute lymphoblastic leukemia, Cancer, Institute, Part, Mycosis fungoides, CRT, Tumor microenvironment, Webcast, Journal, Progression-free survival, PD-L1, IPHA, AstraZeneca, Bristol Myers Squibb, Oxaliplatin, Pharmaceutical industry, Fine chemical, Vaccine, Durvalumab, MD, Nasdaq, Intrinsic and extrinsic properties, Monalizumab

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the quarter ending March 31, 2022.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the quarter ending March 31, 2022.
  • This means our cash position is considerably strengthened to fund our pipeline ambitions into 2024, said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.
  • In March 2022, Innate announced the opening of a new MF all-comers cohort in the TELLOMAK study.
  • Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca

Retrieved on: 
Friday, April 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, NK, Antibody, Novo Nordisk, Safety, Immune system, Euronext Paris, Progression-free survival, PD-L1, PFS, Patient, Oncology, Journal, European Society for Medical Oncology, Lymphatic system, Neoplasm, NSCLC, Lung cancer, ESMO, IPH, ORR, American Journal of Clinical Oncology, Bristol Myers Squibb, Oleclumab, AstraZeneca, IPHA, CRT, Squamous cell carcinoma, Tumor microenvironment, Congress, IIIC, Survival, Sanofi, Pharmaceutical industry, Vaccine, Monalizumab, Durvalumab, Nasdaq, MD, Intrinsic and extrinsic properties

Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate.

Key Points: 
  • Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate.
  • We are very pleased that our key late-stage asset, monalizumab, has progressed into a second Phase 3 trial with our partner, AstraZeneca.
  • Detailed results from the randomized COAST Phase 2 trial were published in the Journal of Clinical Oncology on April 22, 2022.
  • Including the $50 million payment triggered by dosing the first patient in the Phase 3 PACIFIC-9 clinical trial, Innate Pharma has received $450 million to date.

Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress

Retrieved on: 
Thursday, December 9, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Master of Science, FACP, ESMO, CPS, NK, Patient, Antibody, Euronext Paris, Survival rate, IPHA, IPH, Survival, AstraZeneca, Cetuximab, Pharmaceutical industry, Monalizumab, Innate Pharma, MONALIZUMAB, INNATE PHARMA

These data show anti-tumor activity in the first study to evaluate this chemo-free triplet combination in first-line recurrent or metastatic head and neck cancer, said Joyson Karakunnel, M.D., MSc, FACP, Chief Medical Officer of Innate Pharma.

Key Points: 
  • These data show anti-tumor activity in the first study to evaluate this chemo-free triplet combination in first-line recurrent or metastatic head and neck cancer, said Joyson Karakunnel, M.D., MSc, FACP, Chief Medical Officer of Innate Pharma.
  • We believe that the combination of monalizumab with the other two antibodies has the potential to become a new treatment option for patients.
  • After a median follow-up of 16.3 months, preliminary data suggest anti-tumor activity in the triplet of monalizumab, cetuximab and durvalumab in first-line treatment of R/M HNSCC.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress

Retrieved on: 
Thursday, December 2, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Patient, Euronext Paris, Cancer, Cetuximab, Technology, NCR1, Head, Novo Nordisk, Bristol Myers Squibb, IPH, Tumor microenvironment, NK, IPHA, AstraZeneca, DVM, Neck, CET, ESMO, IO, CD16, Antibody, Sanofi, Immune system, Therapy, Lymphatic system, Pharmaceutical industry, Vaccine, Monalizumab, ANKETTM, Innate Pharma, MONALIZUMAB, ANKETTM, INNATE PHARMA

Eric Vivier, Ph.D., DVM, Chief Scientific Officer at Innate Pharma, will present in the NK cell biology educational session.

Key Points: 
  • Eric Vivier, Ph.D., DVM, Chief Scientific Officer at Innate Pharma, will present in the NK cell biology educational session.
  • Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.
  • The ongoing development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer

Retrieved on: 
Friday, September 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Monalizumab, CT, Incidence, Prednisone, European Society for Medical Oncology, Oleclumab, Safety, Warning, Carboplatin, Breathe Me, Doctor of Philosophy, Patient, Infection, ESMO, Company, Ballistic missile, Risk, HIV disease progression rates, Neoplasm, Phase, AEGEAN, ORR, CRT, HR, Solution, MD, Death, Progression-free survival, NSCLC, Hope, Etoposide, Cisplatin, Creatinine, Lung cancer, Pneumonitis, Radiation, Administration, AstraZeneca, PFS, Yale Cancer Center, Oncology, Congress, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Stage III NSCLC, COAST, PACIFIC-R, IMFINZI® (durvalumab), Oleclumab, Monalizumab, AstraZeneca Support Programs, AstraZeneca in lung cancer, AstraZeneca in immunotherapy, AstraZeneca in oncology, AstraZeneca, STAGE III NSCLC, COAST, PACIFIC-R, IMFINZI® (DURVALUMAB), OLECLUMAB, MONALIZUMAB, ASTRAZENECA SUPPORT PROGRAMS, ASTRAZENECA IN LUNG CANCER, ASTRAZENECA IN IMMUNOTHERAPY, ASTRAZENECA IN ONCOLOGY, ASTRAZENECA

The Company is also testing novel combinations with IMFINZI in the Phase II NeoCOAST trial in the neoadjuvant early-stage setting.

Key Points: 
  • The Company is also testing novel combinations with IMFINZI in the Phase II NeoCOAST trial in the neoadjuvant early-stage setting.
  • IMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
  • Sequential vs Concurrent Chemoradiation for Stage III NonSmall Cell Lung Cancer: Randomized Phase III Trial RTOG 9410.
  • Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What is New?